Cationic Microparticles and Emulsions As Effective Delivery Systems for Immune Stimulatory CpG DNA

2004 ◽  
pp. 265-276
Author(s):  
Derek T. O’Hagan ◽  
Manmohan Singh ◽  
Jeffrey B. Ulmer
Author(s):  
Shahin Aghamiri ◽  
Pourya Raee ◽  
Shiva Shahmohamadnejad ◽  
Sasan Shabani ◽  
Jaber Ghorbani ◽  
...  

: The critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle-based siRNA therapeutics. The main challenges to siRNA-based therapeutics becoming a new paradigm in the treatment of prostate cancer stem from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical translation, and commercialization. In this review, we provide cutting-edge advances in nanoparticle-mediated siRNA delivery carriers like polymeric systems, lipid systems, specific systems, and rigid nanoparticles for the treatment of prostate cancer. Moreover, co-delivery of conventional chemotherapy drugs with siRNA as a robust revolutionary strategy for prostate cancer combinational therapy is completely covered.


Author(s):  
Amit Prakash ◽  
Amit Prakash

Oral drug delivery is the most commonly used and preferred route of delivery of pharmaceuticals which has been successfully treating wide number of diseases. The advantages of this method of delivery are patient friendly, cost effective, established delivery system, noninvasiveness and convenient, and In the pharmaceutical field it is the most favored drug delivery system. Oral drug delivery systems along with other effective delivery system types that are effective and promising are discussed in this paper based on the mechanism of drug release.


2015 ◽  
Vol 11 (6) ◽  
pp. 923-941 ◽  
Author(s):  
Dinglin Zhang ◽  
Yanling Wei ◽  
Kai Chen ◽  
Hao Gong ◽  
Songling Han ◽  
...  

Molecules ◽  
2021 ◽  
Vol 27 (1) ◽  
pp. 60
Author(s):  
Andresa Gomes ◽  
Paulo José do Amaral Sobral

The development of plant protein-based delivery systems to protect and control lipophilic bioactive compound delivery (such as vitamins, polyphenols, carotenoids, polyunsaturated fatty acids) has increased interest in food, nutraceutical, and pharmaceutical fields. The quite significant ascension of plant proteins from legumes, oil/edible seeds, nuts, tuber, and cereals is motivated by their eco-friendly, sustainable, and healthy profile compared with other sources. However, many challenges need to be overcome before their widespread use as raw material for carriers. Thus, modification approaches have been used to improve their techno-functionality and address their limitations, aiming to produce a new generation of plant-based carriers (hydrogels, emulsions, self-assembled structures, films). This paper addresses the advantages and challenges of using plant proteins and the effects of modification methods on their nutritional quality, bioactivity, and techno-functionalities. Furthermore, we review the recent progress in designing plant protein-based delivery systems, their main applications as carriers for lipophilic bioactive compounds, and the contribution of protein-bioactive compound interactions to the dynamics and structure of delivery systems. Expressive advances have been made in the plant protein area; however, new extraction/purification technologies and protein sources need to be found Their functional properties must also be deeply studied for the rational development of effective delivery platforms.


Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5192
Author(s):  
Chun Yang ◽  
Rui Wang ◽  
Pierre Hardy

Uveal melanoma (UM) is the most common adult intraocular cancer, and metastatic UM remains deadly and incurable. UM is a complex disease associated with the deregulation of numerous genes and redundant intracellular signaling pathways. As understanding of epigenetic dysregulation in the oncogenesis of UM has increased, the abnormal expression of microRNAs (miRNAs) has been found to be an epigenetic mechanism underlying UM tumorigenesis. A growing number of miRNAs are being found to be associated with aberrant signaling pathways in UM, and some have been investigated and functionally characterized in preclinical settings. This review summarizes the miRNAs with promising therapeutic potential for UM treatment, paying special attention to the therapeutic miRNAs (miRNA mimics or inhibitors) used to restore dysregulated miRNAs to their normal levels. However, several physical and physiological limitations associated with therapeutic miRNAs have prevented their translation to cancer therapeutics. With the advent of nanotechnology delivery systems, the development of effective targeted therapies for patients with UM has received great attention. Therefore, this review provides an overview of the use of nanotechnology drug delivery systems, particularly nanocarriers that can be loaded with therapeutic miRNAs for effective delivery into target cells. The development of miRNA-based therapeutics with nanotechnology-based delivery systems may overcome the barriers of therapeutic miRNAs, thereby enabling their translation to therapeutics, enabling more effective targeting of UM cells and consequently improving therapeutic outcomes.


Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 400
Author(s):  
S. Aishah A. Razak ◽  
Amirah Mohd Gazzali ◽  
Faisalina Ahmad Fisol ◽  
Ibrahim M. Abdulbaqi ◽  
Thaigarajan Parumasivam ◽  
...  

Docetaxel (DCX) is a highly effective chemotherapeutic drug used in the treatment of different types of cancer, including non-small cell lung cancer (NSCLC). The drug is known to have low oral bioavailability due to its low aqueous solubility, poor membrane permeability and susceptibility to hepatic first-pass metabolism. To mitigate these problems, DCX is administered via the intravenous route. Currently, DCX is commercially available as a single vial that contains polysorbate 80 and ethanol to solubilize the poorly soluble drug. However, this formulation causes short- and long-term side effects, including hypersensitivity, febrile neutropenia, fatigue, fluid retention, and peripheral neuropathy. DCX is also a substrate to the drug efflux pump P-glycoprotein (P-gp) that would reduce its concentration within the vicinity of the cells and lead to the development of drug resistance. Hence, the incorporation of DCX into various nanocarrier systems has garnered a significant amount of attention in recent years to overcome these drawbacks. The surfaces of these drug-delivery systems indeed can be functionalized by modification with different ligands for smart targeting towards cancerous cells. This article provides an overview of the latest nanotechnological approaches and the delivery systems that were developed for passive and active delivery of DCX via different routes of administration for the treatment of lung cancer.


2021 ◽  
Vol 28 ◽  
Author(s):  
Yogesh Garg ◽  
Deepak N Kapoor ◽  
Abhishek Kumar Sharma ◽  
Amit Bhatia

Abstract: The transport of drugs to the central nervous system is the most challenging task for conventional drug delivery systems. Reduced permeability of drugs through the blood-brain barrier is a major hurdle in delivering drugs to the brain. Hence, various strategies for improving drug delivery through the blood-brain barrier are currently being explored. Novel drug delivery systems (NDDS) offer several advantages, including high chemical and biological stability, suitability for both hydrophobic and hydrophilic drugs, and can be administered through different routes. Furthermore, the conjugation of suitable ligands with these carriers tend to potentiate targeting to the endothelium of the brain and could facilitate the internalization of drugs through endocytosis. Further, the intranasal route has also shown potential, as a promising alternate route, for the delivery of drugs to the brain. This can deliver the drugs directly to the brain through the olfactory pathway. In recent years, several advancements have been made to target and overcome the barriers of the brain. This article deals with a detailed overview of the diverse strategies and delivery systems to overcome the barriers of the brain for effective delivery of drugs.


2015 ◽  
Vol 16 (4) ◽  
pp. 1095-1101 ◽  
Author(s):  
Kohta Mohri ◽  
Eri Kusuki ◽  
Shozo Ohtsuki ◽  
Natsuki Takahashi ◽  
Masayuki Endo ◽  
...  

Immunotherapy ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 333-349 ◽  
Author(s):  
Mona Yazdani ◽  
Mahmoud Reza Jaafari ◽  
Javad Verdi ◽  
Behrang Alani ◽  
Mahdi Noureddini ◽  
...  

Melanoma is a poor immunogenic cancer and many treatment strategies have been used to enhance specific or nonspecific immunity against it. Dendritic cell (DC)-based cancer vaccine is the most effective therapies that have been used so far. Meanwhile, the efficacy of DC-based immunotherapy relies on critical factors relating to DCs such as the state of maturation and proper delivery of antigens. In this regard, the use of nanoparticulate delivery systems for effective delivery of antigen to ex vivo-generated DC-based vaccines that also poses adjuvanticity would be an ideal approach. In this review article, we attempt to summarize the role of different types of nanoparticulate antigen delivery systems used in the development of ex vivo-generated DC-based vaccines against melanoma and describe their adjuvanticity in mediation of DC maturation, cytoplasmic presentation of antigens to MHC class I molecules, which led to potent antigen-specific immune responses. As were represented, cationic liposomes were the most used approach, which suggest its potential applicability as delivery systems for further experiments in combination with either adjuvants or monoclonal antibodies.


Sign in / Sign up

Export Citation Format

Share Document